CONTROLLED TRIAL OF THE ANTIGONADOTROPIN DANAZOL IN PAINFUL NODULAR BENIGN BREAST DISEASE

In: The Lancet · 1982 · vol. 319(8278) , pp. 928–930 · doi:10.1016/s0140-6736(82)91932-8 · PMID:6122770 · W1982193610
article OA: closed CC0 ⤵ 20 in-corpus citations
View on OpenAlex View on PubMed View at publisher
AI-generated summary by claude@2026-06, 2026-06-21

This controlled trial investigated the efficacy of the antigonadotropin danazol in treating painful nodular benign breast disease.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

In a double-blind crossover study of the effects of the antigonadotropin danazol on pain and nodularity in 28 women with cyclical mastalgia danazol was given at doses of 200 mg/day and 400 mg/day, and the responses were assessed both subjectively and objectively. Danazol caused a significant and progressive decrease in breast pain and nodularity when compared with placebo. Symptoms responded more quickly with the 400 mg/day dose of danazol than with the 200 mg dose, but the larger dose also caused greater side-effects. Danazol is a useful addition to the range of antihormones that can be used to suppress the symptoms of severe hormone-related benign breast disease.

My notes (saved in your browser only)

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (17)

Cited by (20)

Source provenance

openalex
last seen: 2026-05-10T10:18:44.795447+00:00
unpaywall
last seen: 2026-06-13T06:42:57.164913+00:00
License: CC0 · commercial use OK